Baxter/$BAX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Baxter
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
Ticker
$BAX
Sector
Primary listing
NYSE
Industry
Health Care Equipment & Supplies
Headquarters
Employees
38,000
ISIN
US0718131099
Website
Baxter Metrics
BasicAdvanced
$15B
-
-$1.10
0.63
$0.92
2.28%
Price and volume
Market cap
$15B
Beta
0.63
52-week high
$39.71
52-week low
$26.25
Average daily volume
3.4M
Dividend rate
$0.92
Financial strength
Current ratio
2.021
Quick ratio
1.147
Long term debt to equity
136.759
Total debt to equity
191.472
Interest coverage (TTM)
2.48%
Profitability
EBITDA (TTM)
1,955
Gross margin (TTM)
39.27%
Net profit margin (TTM)
-5.20%
Operating margin (TTM)
9.06%
Effective tax rate (TTM)
20.71%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
2.50%
Return on equity (TTM)
-3.51%
Valuation
Price to revenue (TTM)
1.414
Price to book
2.16
Price to tangible book (TTM)
-4.31
Price to free cash flow (TTM)
79.727
Free cash flow yield (TTM)
1.25%
Free cash flow per share (TTM)
37.38%
Dividend yield (TTM)
3.09%
Forward dividend yield
2.28%
Growth
Revenue change (TTM)
-27.67%
Earnings per share change (TTM)
-121.01%
3-year revenue growth (CAGR)
-7.01%
10-year revenue growth (CAGR)
1.51%
3-year earnings per share growth (CAGR)
-19.33%
10-year earnings per share growth (CAGR)
-12.84%
3-year dividend per share growth (CAGR)
-6.35%
10-year dividend per share growth (CAGR)
-7.83%
What the Analysts think about Baxter
Analyst ratings (Buy, Hold, Sell) for Baxter stock.
Bulls say / Bears say
Argus upgraded Baxter International to a 'buy' rating, indicating confidence in the company's future performance. (marketbeat.com)
Baxter's Q2 2024 earnings exceeded expectations, leading to an upward revision of its 2024 EPS guidance. (zacks.com)
The divestiture of the Vantive Kidney Care segment for $3.8 billion is expected to streamline operations and improve financial flexibility. (businesswire.com)
Baxter's CEO, José Almeida, retired immediately, leading to potential uncertainties in leadership and strategic direction. (businesswire.com)
The company reported a significant net loss in Q4 2024, accompanied by goodwill and asset impairments, raising concerns about financial health. (simplywall.st)
Morgan Stanley downgraded Baxter International's price target to $28.00, reflecting a cautious outlook on the stock's future performance. (americanbankingnews.com)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
Baxter Financial Performance
Revenues and expenses
Baxter Earnings Performance
Company profitability
Baxter News
AllArticlesVideos
Mountain Heating and Cooling Transforms Historic Baxter Hotel with Innovative Mitsubishi Heat Pump Installation
GlobeNewsWire·1 week ago
3 Top Goldman Sachs Dividend Stock Picks Have Up to 73% Upside Potential
24/7 Wall Street·2 weeks ago
BAXTER TO Present at Goldman Sachs 46th Annual Global Healthcare Conference 2025
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Jul1
Baxter
Dividend·Payment
$0.17Per share
FAQs
What’s the current market cap for Baxter stock?
Baxter (BAX) has a market cap of $15B as of June 20, 2025.
What is the P/E ratio for Baxter stock?
The price to earnings (P/E) ratio for Baxter (BAX) stock is 0 as of June 20, 2025.
Does Baxter stock pay dividends?
Yes, the Baxter (BAX) stock pays dividends to shareholders. As of June 20, 2025, the dividend rate is $0.92 and the yield is 2.28%. Baxter has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Baxter dividend payment date?
The next Baxter (BAX) dividend payment is scheduled for July 01, 2025.
What is the beta indicator for Baxter?
Baxter (BAX) has a beta rating of 0.63. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.